Literature DB >> 7352750

Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.

B G Gatmaitan, R C Legaspi, H B Levy, A M Lerner.   

Abstract

The purposes of this study were to determine whether the febrile and hypotensive reactions to the administration of polyriboinosinic-polyribocytidylic acid [poly (I)-poly (C)] complexed with poly-L-lysine and carboxymethylcellulose (poly ICLC) (9S) encountered in humans could be duplicated in rabbits, and when such duplication was demonstrated, to ascertain whether these untoward reactions could be avoided by (i) administration of hydrocortisone (HC), (ii) alteration of the route of delivery, or (iii) administration of poly ICLC (4S) an interferon inducer of lower molecular weight. Responses to intravenous poly ICLC (9S) in rabbits reproduced adverse reactions in humans, namely fever and hypotension, and were accompanied by high titers of serum interferon. Continuing investigations showed that (i) intravenous pretreatment of rabbits with HC ameliorated hypotensive responses but markedly diminished interferon induction. When HC was given after poly ICLC (9S), both interferon and hypotension induction were likewise depressed. (ii) Intramuscular or subcutaneous poly ICLC (9S) produced neither high titers of serum interferon nor toxic effects. (iii) Poly ICLC (4S) induced high titers of serum interferon and fever, but no hypotension. Poly ICLC (4S) warrants further study.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7352750      PMCID: PMC283725          DOI: 10.1128/AAC.17.1.49

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Interferon.

Authors:  M Ho; J A Armstrong
Journal:  Annu Rev Microbiol       Date:  1975       Impact factor: 15.500

2.  Semi-micro, dye-binding assay for rabbit interferon.

Authors:  J A Armstrong
Journal:  Appl Microbiol       Date:  1971-04

3.  Double-stranded RNAs (poly I:C) in the prevention of viral infections.

Authors:  M R Hilleman
Journal:  Arch Intern Med       Date:  1970-07

4.  Fate of intravenously administered interferon and the distribution of interferon during virus infections in mice.

Authors:  T P Subrahmanyan; C A Mims
Journal:  Br J Exp Pathol       Date:  1966-04

5.  The effect of altering the size of poly C on the toxicity and antigenicity of poly I:C.

Authors:  G P Lampson; M M Nemes; A K Field; A A Tytell; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1972-12

6.  Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant.

Authors:  W E Houston; C L Crabbs; E L Stephen; H B Levy
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

7.  A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.

Authors:  H B Levy; G Baer; S Baron; C E Buckler; C J Gibbs; M J Iadarola; W T London; J Rice
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

8.  Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.

Authors:  T C Merigan; K H Rand; R B Pollard; P S Abdallah; G W Jordan; R P Fried
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

9.  Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex.

Authors:  M L Sammons; E L Stephen; H B Levy; S Baron; D E Hilmas
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

10.  Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans.

Authors:  K J Champney; D P Levine; H B Levy; A M Lerner
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

View more
  2 in total

1.  Modified polyriboinosinic-polyribocytidylic acid complex: modulation of toxicity for rabbits by alterations in components.

Authors:  B G Gatmaitan; H B Levy; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

2.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.